Enovis (ENOV)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$18.56-4.33%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · ENOV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -60.8% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 5.1% |
Growth built into the price is above our model estimate.
The price assumes 65.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
ENOV — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, the Company issued a press release reporting financial results for the second quarter ended July 3, 2026. A copy of the Company's press release is attached to this report as Exhibit 99.1 and is incorporated into
Why it matters: Sales growth below 4% may show problems in reaching the 2026 revenue goal.
Worry ifQ2 sales growth reported below 4% year over year.
Less concerning ifQ2 sales growth meets or exceeds 4% year over year.
Why it matters: Keeping this range shows good cost control and efficiency.
Supportive ifAdjusted EBITDA is within the $425-435 million range.
Worry ifAdjusted EBITDA is less than $425 million.
Why it matters: Higher gross profit means better efficiency. This is key for long-term success.
Supportive ifQ2 gross profit rises above $370M, indicating better cost control.
Worry ifQ2 gross profit drops below $360M. This shows ongoing operational issues.
Why it matters: A slowdown here could mean less demand. This may hurt overall revenue.
Worry ifReconstructive sales growth was below 6% year over year.
Less concerning ifReconstructive sales growth reported at 6% or higher year over year.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$310 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $654 loss on $10,000 · 6.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,430 loss on $10,000 · 44.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: New products could boost sales growth and improve competitive position.
Supportive ifAnnouncement of a major new product launch that enhances the product line.
Worry ifNo big new product announcements in the next quarter.
Why it matters: This deal will boost Enovis' robotic skills and improve its products.
Supportive ifThe deal will close by the end of 2026 after getting all approvals.
Worry ifThe deal does not close or has big delays after 2026.
Why it matters: This growth is crucial to reaffirming the full-year revenue guidance of $2.31-2.37 billion.
Supportive ifQ3 organic revenue growth reported at 4% or higher.
Worry ifQ3 organic revenue growth is below 4%.
Why it matters: Higher operating income means better control of costs. It also shows more efficiency.
Supportive ifOperating income was above $17 million in Q3.
Worry ifOperating income was below $17 million in Q3.